Dr. Thales Papagiannakopoulos from New York University Grossman School of Medicine

We will have ASHBi Seminar with Dr. Thales Papagiannakopoulos from New York University Grossman School of Medicine.

For more details of the seminar, please check the flyer.

If you have any interest in the topic, you are welcome to attend this seminar.

Program

Title

Mechanisms of Disease Progression in Cancer

Thales Papagiannakopoulos, Ph.D.
Associate Professor, Department of Pathology, Perlmutter Cancer Center, NYU School of Medicine, New York, NY
Director, Molecular Oncology and Tumor Immunology Training Program, NYU School of Medicine, New York, NY

Biography

Thales Papagiannakopoulos obtained his Ph.D. in Molecular, Cellular and Developmental Biology in Dr. Ken Kosik’s lab at UC Santa Barbara (2005-2010). His research focused on uncovering the role of microRNAs in regulating embryonic stem cell pluripotency and cancer. In 2010, he started his postdoctoral studies in Dr. Tyler Jacks’ laboratory at MIT where he studied the molecular mechanisms that contribute to cancer at an organismal level, using autochthonous mouse models of cancer. He pioneered the use of novel CRISPR/Cas9-based genome engineering in pre-clinical lung cancer mouse models.

Thales joined NYU School of Medicine in 2015 as faculty in the Department of Pathology and has since been promoted to associate Professor and is also the Director of the Molecular Oncology and Tumor Immunology Program. Using both mouse and human pre-clinical models, his lab has developed a platform to rapidly characterize the function of clinically relevant lung cancer mutations, elucidate their mechanism of action and identify novel targeted therapies against complex genetic subtypes of lung cancer. Thales’ group has made significant progress in characterizing and identifying novel therapies against the most aggressive genetic subsets of lung cancer with KEAP1 and LKB1 mutations. These findings are of great importance given that patients with these mutations have the worst prognosis of all lung cancer patients and do not respond to standard of care. Finally, his group is investigating how the major genetic subsets of lung cancer differentially impact systemic physiology.

Registration

Pre-registered participants only

Eligibility

Academic researchers and students in Kyoto University

Host

Yasuhiro Murakawa

Contact

Institute for the Advanced Study of Human Biology (WPI-ASHBi)
ashbi-event [at] mail2.adm.kyoto-u.ac.jp
Please change [at] to @.